Background
==========

The obesity-associated insulin resistance has been shown to play an important role in the pathophysiology of overactive bladder in mice \[[@B1],[@B2]\]. Therefore, we evaluated the beneficial effects of long-term administration of the sGC activator BAY 60-2270 in bladders from lean and obese mice.

Methods
=======

Mice were fed for 12 weeks with either a standard chow diet (carbohydrate: 70%; protein: 20%; fat: 10%) or a high fat diet that induces obesity (carbohydrate: 29%; protein: 16%; fat: 55%). Lean and obese mice were orally treated with BAY 60-2770 (1 mg/kg/day, given as daily gavage from the 10^th^ to the 12^th^ week) or its vehicle (Transcutol^®^:Cremophor^®^:water, 1:2:7, v/v/v). Concentration-response curves to full agonist carbachol (CCh, 0.001-100 µM) were obtained. The values of potency (pEC~50~) and maximal responses (E~max~) were calculated. The cGMP levels and Western blotting for α~1~ and β~1~-subunit of sGC in the bladder tissues were also determined.

Results
=======

Contractile response to the muscarinic agonist carbachol was greater (p\<0.05, n=5) in bladder from the obese in comparison with lean group. Long-term treatment with BAY 60-2770 normalized the enhanced contractile responses of the obese group, driving it to control levels (p\<0.05; figure [1](#F1){ref-type="fig"}). The cGMP levels in the bladder tissues from obese group were significantly lower in comparison with lean mice (0.27 ± 0.04 and 0.95 ± 0.14 pmol/mg tissue, respectively, p\<0.05, n=5). Treatment with BAY 60-2770 generated a 10-fold increase (p\<0.01) in the bladder cGMP levels of obese mice, without affecting the levels in the lean group (Figure [2A](#F2){ref-type="fig"}). Protein expression of α~1~ and β~1~ subunits of sGC was decreased by 41% and 43% (p\<0.05) in bladder tissues of obese animals, respectively. However, oral treatment with BAY 60-2770 restored the protein levels of α~1~ and β~1~ subunits to that of lean group (Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}).

![Concentration response curve to cabachol (0.001-100 µM) in isolated bladder from lean and obese mice that received or not BAY 60-2770 (1 mg/Kg, 2 weeks). Data represent mean ± S.E.M.](2050-6511-14-S1-P18-1){#F1}

![Effect of chronic treatment with BAY 60-2770 (1 mg/kg, 2 weeks) on cGMP levels (A) and protein expression of α~1~ (B) and β~1~ (C) subunits of sGC in bladders from lean + vehicle, lean + BAY 60-2770, obese + vehicle and obese + BAY 60-2770 groups. Data are presented as mean ± SEM. ★p \<0.05 in comparison with lean + vehicle group; †p \<0.05 in comparison to obese + vehicle group.](2050-6511-14-S1-P18-2){#F2}

Conclusion
==========

Chronic treatment with BAY 60-2770 results in amelioration of bladder dysfunction in high-fat obese mice.
